Opinion | Open | Published:
Stochastic dynamics and the evolution of mutations in stem cells
BMC Biologyvolume 9, Article number: 41 (2011)
Stem cells are the target of mutations that can lead to life threatening diseases. However, stem cell populations tend to be small and therefore clonal expansion of mutant cells is highly sensitive to stochastic fluctuations. The evolutionary dynamics of mutations in these cells is discussed, taking into consideration the impact of such mutations on the reproductive fitness of cells. We show how stochastic effects can explain clinical observations, including extinction of acquired clonal stem cell disorders.
Cancer is a consequence of multicellularity due to the fact that the cellular genome is under continuous attack from a variety of environmental or metabolic genotoxic agents. Moreover, the DNA replication machinery is not perfect . Hence, the development of mutations in cells is both a natural and artificial - for example, in the case of smoking - process. The finite number of cells and the randomness of cell mutation events lead to a stochastic cell dynamics encompassing several scenarios, including extinction of acquired clonal stem cell disorders, which explains, among other things, spontaneous resolution of diseases. Although many mutations are either neutral  or cytotoxic, some mutations may increase the risk of malignant transformation in which the cell loses regulated growth control giving rise to a clone that may threaten the life of the organism [3, 4]. The risk of acquiring mutations depends on the mutation rate, the population of cells at risk, and the average lifetime of the cell since it is unlikely that multiple simultaneous mutations occur in the same cell [5, 6]. Tissues have evolved an architecture where most cells have a relatively short lifetime and undergo continuous turnover, and this mitigates the accumulation and retention of mutant cells . At the root of this process are the stem cells that are able to maintain tissue integrity because of a dual phenotypic characteristic: self-renewal and production of progeny that can differentiate into various cell lineages that together constitute tissues and organs. One can visualize tissues as having a tree-like organization of cells with stem cells at one extreme and mature, non-dividing cells at the other extreme . Intermediate cells divide, often at relatively high rates, but live for relatively short periods of time. Although mutations can occur at every level of this cell hierarchy, the relatively short lifetime of more mature cell stages means that, in effect, the real risk of long-lasting oncogenic mutations is restricted to the small population of stem cells and early progenitor cells that maintain a given tissue. This, in turn, effectively reduces the probability of the occurrence of mutations, given the small population of cells at risk, despite the fact that a mutation arising in a stem cell can persist for a long time. It is important to point out that the relevance of a mutation is cell context-dependent - a mutation in a gene that is not expressed in a cell is of no consequence to that cell but expression of the gene in more committed cells, downstream of the cell that is the source of the mutation, may lead to a phenotype associated with disease [9, 10]. The natural history of such mutations is the focus of this article. We put forward a possible role of stochastic effects on the generation and fate of mutations acquired by stem cells. Other investigators have also explored the impact of randomness on the fate of tumor cells [11, 12]. We will provide some examples from several well-known blood disorders to illustrate the concepts that will be discussed.
Stochastic dynamics of stem cells
For practical purposes, it is generally accepted that one can consider the number of stem cells contributing to a given tissue (for example, hematopoiesis) as constant (N), especially over short periods of time. As stated before, the probabilistic behavior of the finite cell population is the basis of a stochastic dynamics that can be captured by the Moran process (Figure 1). At any given time step, a cell will be selected for reproduction with a probability that is dependent on its frequency within the population and also proportional to its reproductive fitness (r). Reproduction will increase the net size of the population by one cell, so one must exit the pool if the population is to remain constant. It is assumed that this cell is selected randomly and that it has started the path of differentiation in the sense that such a cell will never again be selected to reproduce in the stem cell pool. Initially, we only have N normal cells and whenever one is selected to divide, there is a probability μ that one of the daughter cells will acquire a mutation in a specific gene (Figure 2a). Therefore, with probability 1 - μ, no mutation will occur. If a mutation occurs, there will then be a new population of (mutant) cells to consider (M) that can also be selected to divide. When mutant cells divide, they give rise to more mutant cells since the probability of correcting a mutation is virtually zero [5, 6]. Mutations can alter the relative reproductive fitness of cells - while the relative fitness of normal cells can be defined to be one, mutant cells will have a relative fitness r (Figure 2a); r < 1 means a lower relative fitness, r > 1 represents a higher relative fitness and r = 1 means that the mutation gives no reproductive advantage compared to the remaining wild-type population. Therefore, assuming that mutant cells are present, the probability (P M ) that a mutant cell is chosen for reproduction at any given time is given by:
where jdenotes the number of mutant cells present at that time (Figure 2c). This probability will vary with time and increases as the population of mutant cells expands. Since at any time point a cell has to be chosen for reproduction, the probability of selecting a normal cell for replication is given by the equation below :
If this process continues for a very long time, the result will ultimately be a state where either all the cells are normal (extinction, Figure 3a) or all the cells are mutated (fixation, Figure 3d). It is possible to calculate the probability that the mutant population will reach fixation, although the time it will take to reach this state may be very long. For example, normal hematopoietic stem cells (HSCs) on average divide once per year . Given that approximately 400 HSCs are actively involved in hematopoiesis [15, 16], one can consider that, on average, approximately one cell is chosen daily for reproduction . Therefore, one can imagine that the process to fixation is generally slow and probably unreachable in the lifetime of a human  unless the reproductive fitness of the mutant is very high, a characteristic that appears to be unusual . This is important - it is well known that in acquired HSC disorders such as chronic myeloid leukemia (CML), leukemic stem cells will generally coexist with normal stem cells . In paroxysmal nocturnal hemoglobinuria (PNH), another clonal stem cell disorder, there is also evidence for the coexistence of normal and mutant clones . Finally, many patients with acute leukemia have been cured with chemotherapy alone, a feat that would be impossible if the normal HSCs were obliterated by the malignant clone. Hence, neoplastic diseases due to acquired mutations are generally characterized by co-existence and competition of normal and mutant stem cells, and therefore the interesting dynamics occur before fixation.
In several bone marrow disorders, disease requires that a specific threshold of mutant stem cells is surpassed: at least 20% of the bone marrow cells have to be blasts to diagnose acute leukemia, and 10% clonal plasma cells are required to diagnose multiple myeloma . Although these thresholds are somewhat artificial, they are meaningful at the clinical level, and they surely correlate with a corresponding burden of mutated stem-cells at the time diseases are diagnosed. We can use the Moran process to define the probability that, at least once, a mutant stem cell can expand to reach a defined threshold required to cause disease. This is again a function of the fitness (r) of the mutant and given by:
where M0 is the initial number of mutant cells and M1 is the number of mutant cells needed to reach the threshold . This probability is independent of the size of the stem cell compartment and depends only on the relative fitness of the mutant population versus normal cells. The above model considers that the HSC pool is homogenous and cells divide symmetrically - differentiation is the result of selection of a cell to differentiate. On average, this behavior gives the same qualitative results as a more elaborate model where the symmetry or lack thereof of stem cell replication is taken into consideration. A model that captures these various dynamics has been described in detail elsewhere . Assuming that a threshold has to be reached to give rise to disease, it is possible to determine the probability distribution functions for the time it will take to reach that threshold as a function of the relative fitness advantage due to a specific mutation (Figure 4). One can make two observations: (i) the probability that the threshold is reached early in time grows as the fitness advantage increases; and (ii) the width of these distributions is inversely related to the fitness advantage. For a small fitness advantage, the time distribution for reaching the threshold is very wide, rendering any summary estimates such as the average meaningless.
The Moran model assumes homogenous mixing of populations; that is, the spatial distribution of the population is not considered. This means that one cell in a specific place reproduces and a cell elsewhere is chosen for death, a scenario perhaps easiest to accept in small populations of stem cells, such as in an individual colonic crypt . However, the Moran process may also be of relevance to hematopoiesis, where stem cells are distributed throughout the bone marrow, since HSCs appear to be coupled chemically and perhaps even neurologically [24, 25], which may allow them to function as a homogenous population. Perhaps the best example of this tight coupling is the constant frequency of oscillations in a disease known as cyclic hematopoiesis (neutropenia). In this condition, the neutrophil count (and that of other types of cell) oscillates with a regular frequency (19 to 21 days) for the lifetime of the person . For this process to be sustained, tight coupling of cellular reproduction in time must be present, even though the cells are scattered in space - otherwise the oscillations will dissipate as cell reproduction loses synchronization . On the other hand, Moran dynamics introduced here does not capture the symmetric or asymmetric division of individual cells and therefore the process can only provide an average account of the population dynamics. However, one can argue that it is the population that evolves and not the individual cell(s). An analysis of the impact of the symmetry of cell division on mutant clone dynamics has been described elsewhere .
Application of stochastic dynamics to disease modeling: clonal expansion
Reproduction of mutant cells leads to their expansion into a clone. How frequently the cells are chosen for replication depends on their relative frequency in the population and on their relative reproductive fitness (Figure 2b,c). Although cells with a higher relative fitness will be more likely to be selected for reproduction, it does not follow that cells with neutral or even reduced relative fitness cannot expand. Although the probability that a neutral clone will expand to reach a given threshold is small, this can happen and may lead to disease. The best example is PNH, an acquired clonal HSC disorder due to a mutation in the PIG-A gene. The ultimate result of this mutation is loss of expression of glycosylphosphatidylinositol (GPI)-anchored proteins from the plasma membrane of cells (for example, CD55 and CD59), which renders red blood cells unusually sensitive to complement-mediated lysis, thus leading to intravascular hemolysis and hemoglobinuria . To date, no fitness advantage has been identified in cells with this mutation (summarized in ). We have shown that a Moran model of HSC dynamics can predict various aspects of the natural history of PNH. The model assumes that the PIG-A mutation gives no fitness advantage to the HSC (neutral drift). We introduced in the model (i) the number of active HSCs that are contributing to hematopoiesis, (ii) the rate of replication of the cells (approximately once per year) , (iii) the known mutation rate in the PIG-A gene  and an acceptable threshold of mutant cells needed to cause disease . Extended simulations of the process lead to predictions of the incidence of PNH in the general population and an average clone size within patients  in good agreement with available data. Therefore, clonal expansion by neutral drift can lead to disease, and perhaps explain why a disease such as PNH is so rare.
Expression of BCR-ABL in HSCs leads to a disease resembling chronic phase CML in experimental animals, suggesting that this oncogene is enough to explain the early chronic phase of the disease [31, 32]. Modeling of the dynamics in CML suggests that BCR-ABL does not give a fitness advantage to the mutant stem cells [33–35]. This is now supported by direct and indirect experimental evidence [36, 37]. Neutral drift implies that expansion of this population of CML stem cells will generally be slow and, as a consequence, the clone size will be small. In addition, there is a reasonable chance that the mutant stem cell clone will be stochastically eliminated . Can such an event happen? Currently, patients with CML are treated with tyrosine kinase inhibitors, such as imatinib or nilotinib, that have no detectable effect on the CML stem cells . Therefore, it has been assumed that imatinib cannot cure patients with this disease and patients should continue therapy indefinitely. However, stochastic extinction implies that imatinib can effectively cure some patients even without directly killing the CML stem cells. In such cases, therapy could be stopped without relapse of the disease. The major issue here is how long treatment should continue since one wants to be certain that the CML stem cells have been stochastically eliminated before withdrawing therapy. This issue has been addressed using a computational model of CML dynamics under imatinib therapy that takes into consideration stochastic dynamics within the stem cell pool. Starting from diagnosis, it may take up to 5 years or more for the patient to reach a major molecular response (>4 log reduction in disease burden) and probably longer to achieve a complete molecular response. If therapy were continued for another 2 years after reaching this threshold, the probability of relapse becomes small  (below 2%). Recent data from the French CML group suggests that indeed some patients may be able to stop therapy without relapsing, although longer follow-up is needed .
Stochastic dynamics of latency
It is not uncommon to find mutations in disease-associated genes in healthy adults. For example, almost every human has a PIG-A mutated clone . Small clones harboring the Philadelphia chromosome and expressing BCR-ABL have been described , and the JAK2V617F mutation, which is normally associated with chronic myeloid neoplasms, may be present in up to 1% of the population [42, 43]. The origins, implications and dynamics of these observations have been discussed elsewhere . PIG-A mutant clones may disappear during follow up  or fluctuate stochastically but others may persist without detectable evolution, as has been reported in individuals with JAK2V617F essential thrombocythemia . Latency is therefore compatible with stochastic behavior within the stem cell pool (Figure 4). However, there is at least one other scenario that can explain latency. In many if not all tumors, acquisition of the full cancer phenotype may require the serial accumulation of gain-of-function mutations in oncogenes and loss-of-function mutations in tumor suppressor genes, as well as epigenetic changes. For example, the adenoma to carcinoma sequence in colon cancer is associated with mutations in APC, K-RAS, and TP53 amongst others . Hence, it is possible that a transient clone may arise harboring one of these mutations but, without the accumulation of additional mutations, it may not grow enough to be detectable, thus remaining a latent clone.
The stochastic dynamics associated with the Moran process predicts the possibility of extinction of any mutant clone, irrespective of its relative fitness. This phenomenon, however, becomes quite likely when the mutation either gives a relative fitness disadvantage or is neutral. It is important to remember that even for mutations that increase the reproductive fitness of the cell, extinction is still possible. One can computationally show that even for a mutation that increases the relative fitness of cells by a factor of two, which, in evolutionary terms, constitutes a very high fitness advantage, the probability of extinction of the mutant cell is still about 50% . Of course, as the cell expands into a clone, extinction becomes less likely, explaining why most tumors do not resolve without therapy.
However, stochastic extinction is not just an in silico curiosity: there is evidence that clonal extinction occurs in vivo. Let us discuss several examples. First, healthy individuals have been shown to have small clones with the Bcr-Abl oncogene but not necessarily develop CML . In some of these individuals, the clone will disappear in time without any specific therapy. Another example is patients who have been diagnosed with myelodysplastic syndromes, a group of clonal preleukemic stem cell disorders, that in some cases resolve without any specific therapy directed at the malignant clone . One of the best examples of clonal extinction is that observed in transient myeloproliferative disorder (TMD), which occurs in a significant fraction of children with Down's syndrome and is often diagnosed at or soon after birth [48, 49]. The malignant cells appear to have a very 'primitive origin', implying mutations in early progenitor cells if not in the HSCs. In the vast majority of patients, the condition resolves with minimal or no therapy, although it is lethal in some cases. One of the fascinating features about PNH is that the disease sometimes resolves in the absence of therapy (other than allogeneic bone marrow transplantation) that directly targets the mutant clone. The frequency of this spontaneous resolution is in the range of 12 to 15% and has been confirmed using both the Ham's test (a test of the sensitivity of red cells to complement-mediated lysis) and the more sensitive flow cytometry assay (which directly determines the fraction of cells that belong to the PNH clone by detection of CD55 and CD59 positive and negative cells) [50, 51]. While no clear explanation has been provided for this phenomenon, our own simulations of HSC dynamics predict that clonal extinction after diagnosis can occur in about 12% of patients, in excellent agreement with epidemiological data .
We wish to remind the reader that, in principle, other potential explanations, alternative to stochastic extinction, could exist for the disappearance of mutant clones. For example, our model does not consider the potential impact of immune surveillance and elimination of tumor cells by the immune response. There is some evidence for this phenomenon, especially in the context of allogeneic stem cell transplantation. However, elimination of a mutant clone due to an autologous immune attack is also possible. These scenarios are not mutually exclusive and perhaps either occurs in a subset of patients.
Stochastic behavior is an intrinsic aspect of life - both at the cellular and organismal level. Acquisition of mutations and the evolution of clones are processes that are highly sensitive to stochastic effects since the population under consideration is often small. Mathematically, it is as if cells play dice - many times the impact of such a gamble is inconsequential, at other times it leads to the loss of a particular cell lineage. Unfortunately, there are times when acquired mutations lead to clonal expansion and disease. Depending on the fitness of the mutant clone, stochastic extinction is possible, especially when the population is small and the relative fitness advantage minimal compared to normal cells but also even when the population is not small or the fitness advantage is significant. It is in these circumstances that chance may play a role in cure versus disease. Reduction in disease burden to low levels could, in principle, lead to clonal extinction, especially if the fitness advantage of the mutant cells can be reduced by therapy.
Kunkel TA, Bebenek K: DNA replication fidelity. Annu Rev Biochem. 2000, 69: 497-529. 10.1146/annurev.biochem.69.1.497.
Kimura M: DNA and the neutral theory. Philos Trans R Soc Lond B Biol Sci. 1986, 312: 343-354. 10.1098/rstb.1986.0012.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.
Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med. 2004, 10: 789-799. 10.1038/nm1087.
Traulsen A, Pacheco JM, Dingli D: On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells. 2007, 25: 3081-3084. 10.1634/stemcells.2007-0427.
Dingli D, Pacheco JM, Traulsen A: Multiple mutant clones in blood rarely coexist. Phys Rev. 2008, 77: 021915-
Cairns J: Mutation selection and the natural history of cancer. Nature. 1975, 255: 197-200. 10.1038/255197a0.
Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.
Pacheco JM, Traulsen A, Antal T, Dingli D: Cyclic neutropenia in mammals. Am J Hematol. 2008, 83: 920-921. 10.1002/ajh.21295.
Dingli D, Antal T, Traulsen A, Pacheco JM: Progenitor cell self-renewal and cyclic neutropenia. Cell Prolif. 2009, 42: 330-338. 10.1111/j.1365-2184.2009.00598.x.
Yakovlev A, Boucher K, DiSario J: Modeling insight into spontaneous regression of tumors. Math Biosci. 1999, 155: 45-60. 10.1016/S0025-5564(98)10052-4.
Michor F, Nowak MA, Frank SA, Iwasa Y: Stochastic elimination of cancer cells. Proc Biol Sci. 2003, 270: 2017-2024. 10.1098/rspb.2003.2483.
Dingli D, Traulsen A, Pacheco JM: Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle. 2007, 6: 461-466. 10.4161/cc.6.4.3853.
Rufer N, Brummendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, Schulzer M, Lansdorp PM: Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med. 1999, 190: 157-167. 10.1084/jem.190.2.157.
Buescher ES, Alling DW, Gallin JI: Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool. J Clin Invest. 1985, 76: 1581-1584. 10.1172/JCI112140.
Dingli D, Pacheco JM: Allometric scaling of the active hematopoietic stem cell pool across mammals. PLoS ONE. 2006, 1: e2-10.1371/journal.pone.0000002.
Lopes JV, Pacheco JM, Dingli D: Acquired hematopoietic stem-cell disorders and mammalian size. Blood. 2007, 110: 4120-4122. 10.1182/blood-2007-05-089805.
Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA: Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA. 2010, 107: 18545-18550. 10.1073/pnas.1010978107.
Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP: Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood. 1998, 91: 630-640.
Araten DJ, Bessler M, McKenzie S, Castro-Malaspina H, Childs BH, Boulad F, Karadimitris A, Notaro R, Luzzatto L: Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones. Leukemia. 2002, 16: 2243-2248. 10.1038/sj.leu.2402694.
Jaffe ES, Harris NL, Stein H, Vardiman JW: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 2001, Lyon: IARC Press
Dingli D, Traulsen A, Michor F: (A)Symmetric stem cell replication and cancer. PLoS Comput Biol. 2007, 3: e53-10.1371/journal.pcbi.0030053.
Johnston MD, Edwards CM, Bodmer WF, Maini PK, Chapman SJ: Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc Natl Acad Sci USA. 2007, 104: 4008-4013. 10.1073/pnas.0611179104.
Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS: Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006, 124: 407-421. 10.1016/j.cell.2005.10.041.
Mendez-Ferrer S, Lucas D, Battista M, Frenette PS: Haematopoietic stem cell release is regulated by circadian oscillations. Nature. 2008, 452: 442-447. 10.1038/nature06685.
Haurie C, Dale DC, Mackey MC: Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. Blood. 1998, 92: 2629-2640.
Luzzatto L, Bessler M, Rotoli B: Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?. Cell. 1997, 88: 1-4. 10.1016/S0092-8674(00)81850-4.
Dingli D, Luzzatto L, Pacheco JM: Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA. 2008, 105: 18496-18500. 10.1073/pnas.0802749105.
Araten DJ, Luzzatto L: The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006, 108: 734-736. 10.1182/blood-2006-01-0256.
Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socié G, International PNH Interest Group: Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005, 106: 3699-3709. 10.1182/blood-2005-04-1717.
Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990, 247: 824-830. 10.1126/science.2406902.
Zhao RC, Jiang Y, Verfaillie CM: A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood. 2001, 97: 2406-2412. 10.1182/blood.V97.8.2406.
Dingli D, Traulsen A, Pacheco JM: Chronic myeloid leukemia: origin, development, response to therapy, and relapse. Clin Leukemia. 2008, 2: 133-139. 10.3816/CLK.2008.n.017.
Lenaerts T, Pacheco JM, Traulsen A, Dingli D: Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica. 2010, 95: 900-907. 10.3324/haematol.2009.015271.
Dingli D, Traulsen A, Lenaerts T, Pacheco JM: Evolutionary dynamics of chronic myeloid leukemia. Genes Cancer. 2010, 1: 309-315. 10.1177/1947601910371122.
Schemionek M, Elling C, Steidl U, Bäumer N, Hamilton A, Spieker T, Göthert JR, Stehling M, Wagers A, Huettner CS, Tenen DG, Tickenbrock L, Berdel WE, Serve H, Holyoake TL, Müller-Tidow C, Koschmieder S: BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood. 2010, 115: 3185-3195. 10.1182/blood-2009-04-215376.
Järås M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, Lassen C, Olofsson T, Bjerrum OW, Richter J, Fioretos T: Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010, 107: 16280-16285. 10.1073/pnas.1004408107.
Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL: Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007, 109: 4016-4019. 10.1182/blood-2006-11-057521.
Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Français des Leucémies Myéloïdes: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11: 1029-1035. 10.1016/S1470-2045(10)70233-3.
Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L: Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA. 1999, 96: 5209-5214. 10.1073/pnas.96.9.5209.
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998, 92: 3362-3367.
Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, Fu X, Zhao ZJ: JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007, 109: 339-342. 10.1182/blood-2006-03-009472.
Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE: The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011, 96: 450-453. 10.3324/haematol.2010.033191.
Traulsen A, Pacheco JM, Luzzatto L, Dingli D: Somatic mutations and the hierarchy of hematopoiesis. Bioessays. 2010, 32: 1003-1008. 10.1002/bies.201000025.
Gale RE, Allen AJ, Nash MJ, Linch DC: Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood. 2007, 109: 1241-1243.
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 1990, 61: 759-767. 10.1016/0092-8674(90)90186-I.
Broun ER, Heerema NA, Tricot G: Spontaneous remission in myelodysplastic syndrome. A case report. Cancer Genet Cytogenet. 1990, 46: 125-128. 10.1016/0165-4608(90)90018-6.
Lange B: The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000, 110: 512-524. 10.1046/j.1365-2141.2000.02027.x.
Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ: A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006, 107: 4606-4613. 10.1182/blood-2005-06-2448.
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV: Natural history of paroxysmal nocturnal hemoglobinuria. N Eng J Med. 1995, 333: 1253-1258. 10.1056/NEJM199511093331904.
Boschetti C, Fermo E, Bianchi P, Vercellati C, Barraco F, Zanella A: Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2004, 77: 36-44. 10.1002/ajh.20144.